Form 4: Oncocyte Corp CEO Josh Riggs Acquires 90,000 Options
SEC Form 4 Filing
Oncocyte Corp CEO and President Josh Riggs reports the acquisition of 90,000 options to purchase common stock.
Summary
- On May 20, 2024, Josh Riggs, CEO and President of Oncocyte Corp, reported acquiring 90,000 options to purchase common stock at an exercise price of $2.76.
- The options vest over a period of four years, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments commencing one year after the grant date.
- Following the transaction, Riggs directly owns 90,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of stock options granted to the CEO, which is a common practice in executive compensation.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership by a company insider. It's a routine part of executive compensation and doesn't necessarily indicate a significant shift in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of transaction: Josh Riggs acquired 90,000 options. |
| 05/20/2024 | Date of report. |
| 05/20/2034 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.